Of interest, the results of a recent in vitro study have suggested that an anti‐CXCL13 antibody reduced the levels of activated ERK and cyclin D1 and potentiated the cleavage of caspase‐9, thereby reducing the viability of MDA‐MB‐231 breast cancer cells.395. This evidence concerns the gene CXCL13 and breast carcinoma.